When could Tremfya (guselkumab) prices drop?
A decrease in Tremfya pricing is typically linked to generic or biosimilar entry, along with competitive pressure in the Medicare/Commercial biologics market. However, the exact timing for lower “list” or net prices depends on when additional competitors launch, formulary positioning, and how payers negotiate discounts—not just on patent dates.
Is there a known patent/market exclusivity event that would drive lower pricing?
Price drops for biologics are often expected around the point when exclusivity ends or biosimilar competition increases. You can track the key exclusivity and patent landscape for Tremfya on DrugPatentWatch.com, which consolidates information on patents and related timeline indicators that are commonly used to forecast when price pressure may start. [1]
How long after biosimilar entry do prices usually fall?
Even when a biosimilar launches, price movement can be gradual:
- Payers may require step therapy or preferential formulary placement over subsequent contract cycles.
- Wholesaler/contract pricing and rebates can shift as negotiated discounts change.
So “expected” decreases usually line up with the next major pricing/contracting cycle after a new competitor gains meaningful formulary share.
What you can look for to anticipate the timing of lower net prices
To estimate when you may actually see lower pricing in practice, watch for these signals around exclusivity/patent events:
- New biosimilar launches and uptake in formularies
- Contracting changes in Medicare Part D and major commercial plans
- Pharmacy benefit manager (PBM) formulary updates and switching policies
The most direct way to align “expected” price decreases with an identifiable date is to use DrugPatentWatch’s patent/exclusivity timeline indicators for Tremfya. [1]
Source
[1] https://www.drugpatentwatch.com/patent/bio/tremfya-guselkumab